Health economic evidence of 5% lidocaine medicated plaster in post-herpetic neuralgia

References

• JohnsonRWWhittonTLManagement of herpes zoster (shingles) and postherpetic neuralgiaExpert Opin Pharmacother20045355155915013924
   PubMed Web of Science ®Google Scholar
• DworkinRHPortenoyRKPain and its persistence in herpes zosterPain1996672–32412518951917
   PubMed Web of Science ®Google Scholar
• PhilipAThakurRPost herpetic neuralgiaJ Palliat Med201114676577321651364
   PubMed Web of Science ®Google Scholar
• LydickEEpsteinRSHimmelbergerDWhiteCJHerpes zoster and quality of life: a self-limited disease with severe impactNeurology19954512 Suppl 8S52S538545021
   PubMed Web of Science ®Google Scholar
• Graff-RadfordSBKamesLDNaliboffBDMeasure of psychological adjustment and perception of pain in postherpetic neuralgia and trigeminal neuralgiaClin J Pain1986255
   Google Scholar
• VolpiASevere complications of herpes zosterHerpes200714Suppl 2353917939894
   PubMedGoogle Scholar
• SchmaderKEEpidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathyClin J Pain200218635035412441828
   PubMed Web of Science ®Google Scholar
• GialloretiLEMeritoMPezzottiPEpidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: a retrospective, population-based studyBMC Infect Dis20101023020682044
   PubMed Web of Science ®Google Scholar
• DworkinRHO’ConnorABBackonjaMPharmacologic management of neuropathic pain: evidence-based recommendationsPain2007132323725117920770
   PubMed Web of Science ®Google Scholar
• AttalNCruccuGBaronREuropean Federation of the Neurological SocietiesEFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revisionEur J Neurol2010179e1113e1188
   PubMed Web of Science ®Google Scholar
• DubinskyRMKabbaniHEl-ChamiZBoutwellCAliHQuality Standards Subcommittee of the American Academyof NeurologyPractice parameter: treatment of postherpetic neuralgia: an evidence-based report of the Quality Standards Subcommittee of the American Academy of NeurologyNeurology 282004636959965
   PubMed Web of Science ®Google Scholar
• DouglasMWJohnsonRWCunninghamALTolerability of treatments for postherpetic neuralgiaDrug Saf200427151217123315588117
   PubMed Web of Science ®Google Scholar
• BaronRMayoralVLeijonGBinderASteigerwaldISerpellM5% lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT studyCurr Med Res Opin20092571663167619485723
   PubMed Web of Science ®Google Scholar
• HirshATAtchisonJWBergerJJPatient satisfaction with treatment for chronic pain: predictors and relationship to complianceClin J Pain200521430231015951647
   PubMed Web of Science ®Google Scholar
• ChristoPJHobelmannGMaineDNPost-herpetic neuralgia in older adults: evidence-based approaches to clinical managementDrugs Aging200724111917233544
   PubMed Web of Science ®Google Scholar
• ViewegWVWoodMATricyclic antidepressants, QT interval prolongation, and torsade de pointesPsychosomatics200445537137715345781
   PubMed Web of Science ®Google Scholar
• VadaloucaASiafakaIArgyraEVrachnouEMokaETherapeutic management of chronic neuropathic pain: an examination of pharmacologic treatmentAnn N Y Acad Sci2006108816418617192564
   PubMed Web of Science ®Google Scholar
• van SeventerRSadoskyALuceroMDukesEA cross-sectional survey of health state impairment and treatment patterns in patients with postherpetic neuralgiaAge Ageing200635213213716431855
   PubMed Web of Science ®Google Scholar
• BealBMoeller-BertramTSchillingJMWallaceMSGabapentin for once-daily treatment of post-herpetic neuralgia: a reviewClin Interv Aging2012724925522866002
   PubMed Web of Science ®Google Scholar
• RowbothamMHardenNStaceyBBernsteinPMagnus-MillerLGabapentin for the treatment of postherpetic neuralgia: a randomized controlled trialJAMA199828021183718429846778
   PubMed Web of Science ®Google Scholar
• RiceASMatonSGabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled studyPain200194221522411690735
   PubMed Web of Science ®Google Scholar
• BennettMISimpsonKHGabapentin in the treatment of neuropathic painPalliat Med200418151114982201
   PubMed Web of Science ®Google Scholar
• PfizerLyrica® Summary of Product Characteristics Available from: http://www.medicines.org.uk/emc/medicine/14651Accessed September 16, 2013
   Google Scholar
• SemelDMurphyTKZlatevaGCheungREmirBEvaluation of the safety and efficacy of pregabalin in older patients with neuropathic pain: results from a pooled analysis of 11 clinical studiesBMC Fam Pract2010118521054853
   PubMed Web of Science ®Google Scholar
• DworkinRHCorbinAEYoungJPJrPregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trialNeurology20036081274128312707429
   PubMed Web of Science ®Google Scholar
• SabatowskiRGalvezRCherryDAPregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trialPain20041091–2263515082123
   PubMed Web of Science ®Google Scholar
• DerrySLloydRMooreRAMcQuayHJTopical capsaicin for chronic neuropathic pain in adultsCochrane Database Syst Rev20094CD00739319821411
   PubMed Web of Science ®Google Scholar
• WebsterLRNunezMTarkMDTolerability of NGX-4010, a capsaicin 8% dermal patch, following pretreatment with lidocaine 2.5%/prilocaine 2.5% cream in patients with post-herpetic neuralgiaBMC Anesthesiol2011112522182397
   PubMed Web of Science ®Google Scholar
• WebsterLRPeppinJFMurphyFTTobiasJKVanhoveGFTolerability of NGX-4010, a capsaicin 8% patch, in conjunction with three topical anesthetic formulations for the treatment of neuropathic painJ Pain Res2012571322328830
   PubMedGoogle Scholar
• MeierTWasnerGFaustMEfficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomized, double-blind, placebo-controlled studyPain20031061–215115814581122
   PubMed Web of Science ®Google Scholar
• RowbothamMCDaviesPSFieldsHLTopical lidocaine gel relieves postherpetic neuralgiaAnn Neurol19953722462537847866
   PubMed Web of Science ®Google Scholar
• RowbothamMCDaviesPSVerkempinckCGalerBSLidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgiaPain199665139448826488
   PubMed Web of Science ®Google Scholar
• GalerBSRowbothamMCPeranderJFriedmanETopical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment studyPain199980353353810342414
   PubMed Web of Science ®Google Scholar
• GalerBSJensenMPMaTDaviesPSRowbothamMCThe lidocaine patch 5% effectively treats all neuropathic pain qualities: results of a randomized, double-blind, vehicle-controlled, 3-week efficacy study with use of the neuropathic pain scaleClin J Pain200218529730112218500
   PubMed Web of Science ®Google Scholar
• BinderABruxelleJRogersPHansGBöslIBaronRTopical 5% lidocaine (lignocaine) medicated plaster treatment for post-herpetic neuralgia: results of a double-blind, placebo-controlled, multinational efficacy and safety trialClin Drug Investig2009296393408
   PubMed Web of Science ®Google Scholar
• ArgoffCEGalerBSJensenMPOlekaNGammaitoniAREffectiveness of the lidocaine patch 5% on pain qualities in three chronic pain states: assessment with the Neuropathic Pain ScaleCurr Med Res Opin200420Suppl 2S21S2815563743
   PubMed Web of Science ®Google Scholar
• KatzNPGammaitoniARDavisMWDworkinRHLidocaine patch 5% reduces pain intensity and interference with quality of life in patients with postherpetic neuralgia: an effectiveness trialPain Med20023432433215099237
   PubMed Web of Science ®Google Scholar
• GammaitoniAROlekaNGalerBSLidocaine patch 5% improves outcomes for post-herpetic neuralgia patients receiving COX-2/anti-inflammatory, opioid or adjuvant analgesicsAmerican Pain Society 24th Annual Scientific Meeting2005Boston, MA, USA
   Google Scholar
• WhiteREHawkinsKA comparative cost analysis on the use of lidocaine patch 5% and branded and generic gabapentin for treatment of chronic neuropathic and non-neuropathic pain conditionsArthritis Rheum2005529S527
   Google Scholar
• HansGSabatowskiRBinderABoeslIRogersPBaronREfficacy and tolerability of a 5% lidocaine medicated plaster for the topical treatment of post-herpetic neuralgia: results of a long-term studyCurr Med Res Opin20092551295130519366301
   PubMed Web of Science ®Google Scholar
• GalerBSGammaitoniARMore than 7 years of consistent neuropathic pain relief in geriatric patientsArch Intern Med2003163562812622611
   PubMedGoogle Scholar
• HempenstallKNurmikkoTJJohnsonRWA’HernRPRiceASAnalgesic therapy in postherpetic neuralgia: a quantitative systematic reviewPLoS Med200527e16416013891
   PubMed Web of Science ®Google Scholar
• WolffRFBalaMMWestwoodMKesselsAGKleijnenJ5% lidocaine-medicated plaster vs other relevant interventions and placebo for post-herpetic neuralgia (PHN): a systematic reviewActa Neurol Scand2011123529530921039364
   PubMed Web of Science ®Google Scholar
• MickGCorrea-IllanesGTopical pain management with the 5% lidocaine medicated plaster-a reviewCurr Med Res Opin201228693795122551228
   PubMed Web of Science ®Google Scholar
• UberallMAMüller-SchwefeGHPatient perceptions associated with the 5% lidocaine medicated plaster in daily practiceCurr Med Res Opin201228690190922506624
   PubMed Web of Science ®Google Scholar
• DelormeCNavezMLLegoutVDeleensRMoyseDTreatment of neuropathic pain with 5% lidocaine-medicated plaster: Five years of clinical experiencePain Res Manag201116425926322059196
   PubMed Web of Science ®Google Scholar
• SabatowskiRHansGTackenIKapanadzeSBuchheisterBBaronRSafety and efficacy outcomes of long-term treatment up to 4 years with 5% lidocaine medicated plaster in patients with post-herpetic neuralgiaCurr Med Res Opin20122881337134622769236
   PubMed Web of Science ®Google Scholar
• DakinHNuijtenMLiedgensHNautrupBPCost-effectiveness of a lidocaine 5% medicated plaster relative to gabapentin for postherpetic neuralgia in the United KingdomClin Ther20072971491150717825701
   PubMed Web of Science ®Google Scholar
• DakinHNuijtenMLiedgensHNautrupBPCost-utility analysis evaluating lidocaine 5% medicated plaster relative to gabapentin for postherpetic neuralgia in ScotlandValue Health2007103A9A10
   Web of Science ®Google Scholar
• DakinHNuijtenMPoulsen NautrupBLiedgensHCost- effectiveness of a lidocaine plaster relative to pregabalin in the treatment of postherpetic neuralgia in ScotlandValue Health200710A240
   Web of Science ®Google Scholar
• LiedgensHHertelNGabrielACost-effectiveness analysis of a lidocaine 5% medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia: a German perspectiveClin Drug Investig2008289583601
   PubMed Web of Science ®Google Scholar
• NuijtenMPaisBRLiedgensHvan WijckAJCost-utility analysis evaluating the lidocaine 5% medicated plaster relative to gabapentin and pregabalin for post-herpetic neuralgia in The NetherlandsValue Health2008115A601
   Web of Science ®Google Scholar
• RitchieMLiedgensHNuijtenMCost effectiveness of a lidocaine 5% medicated plaster compared with pregabalin for the treatment of postherpetic neuralgia in the UK: a Markov model analysisClin Drug Investig20103027187
   PubMed Web of Science ®Google Scholar
• NuijtenMHidalgoAObradovicMLiedgensHCost-effectiveness of a lidocaine plaster relative to gabapentin and pregabalin in the treatment of postherpetic neuralgia in SpainValue Health2010137A468
   Google Scholar
• NuijtenMGouveiaMBrandaoJFleischhacklRHLiedgensHCost-effectiveness of lidocaine 5% medicated plaster relative to pregabalin in the treatment of post-herpetic neuralgia in Austria and PortugalPoster session presented at the 13th World Congress on Pain2010Montréal, Canada Available from: http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=2ec7e761-d49a-463b-ac8f-add5cb56402d&cKey=6bca4996-f6e0-49cf-95db-857fb675837c&mKey=%7b3F846F23-E219-40A0-B790-DBC3F75684FD%7d
   Google Scholar
• NuijtenMPaisBRBergmannALiedgensHCost-utility analysis evaluating the lidocaine 5% medicated plaster relative to pregabalin for post-herpetic neuralgia in SwedenEur J Pain2010Suppl 4171
   Google Scholar
• CepedaMSFarrarJTEconomic evaluation of oral treatments for neuropathic painJ Pain20067211912816459277
   PubMed Web of Science ®Google Scholar
• ArmstrongEPMaloneDCMcCarbergBPanaritesCJPhamSVCost-effectiveness analysis of a new 8% capsaicin patch compared to existing therapies for postherpetic neuralgiaCurr Med Res Opin201127593995021375358
   PubMed Web of Science ®Google Scholar
• SmithKJRobertsMSSequential medication strategies for postherpetic neuralgia: a cost-effectiveness analysisJ Pain20078539640417241821
   PubMed Web of Science ®Google Scholar
• KirsonNYIvanovaJIBirnbaumHGComparing healthcare costs of Medicaid patients with postherpetic neuralgia (PHN) treated with lidocaine patch 5% versus gabapentin or pregabalinJ Med Econ201013348249120684669
   PubMedGoogle Scholar
• RollasonVVogtNReduction of polypharmacy in the elderly: a systematic review of the role of the pharmacistDrugs Aging2003201181783212964888
   PubMed Web of Science ®Google Scholar
• BanerjeeAMbamaluDEbrahimiSKhanAAChanTFThe prevalence of polypharmacy in elderly attenders to an emergency department – a problem with a need for an effective solutionInt J Emerg Med2011412221635734
   PubMedGoogle Scholar
• ZiereGDielemanJPHofmanAPolsHAvan der CammenTJStrickerBHPolypharmacy and falls in the middle age and elderly populationBr J Clin Pharmacol200661221822316433876
   PubMed Web of Science ®Google Scholar
• Di LegamiVGianinoMMCiofi degli AttiMEpidemiology and costs of herpes zoster: background data to estimate the impact of vaccinationVaccine200725437598760417889410
   PubMed Web of Science ®Google Scholar